Corporate Information

NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA that develops, manufactures and markets innovative products for the treatment of End-Stage Renal Disease (ESRD) and acute kidney failure.

NxStage is leading a movement to transform kidney care, by offering patients the choice of receiving their dialysis treatments at home. Since April 2013, NxStage has been selling home haemodialysis products and services directly in the United Kingdom through its subsidiary, NxStage Medical UK, Ltd.

The UK team is solely dedicated to supporting home haemodialysis in the United Kingdom through customised clinical, commercial, and educational support for UK centres.

The NxStage® System One is at the heart of the movement to expand patient choice, and was specifically designed to overcome the challenges of using traditional dialysis machines at home. The size, simplicity, and portability of the NxStage System One provides flexible treatment options to help fit each patient's treatment around their life and lifestyle.

The Department of Health in the United Kingdom recognises the importance of home haemodialysis. In fact, in 2002, the National Institute for Health and Care Excellence (NICE) recommended that all suitable patients should be offered the choice of home haemodialysis.

We're committed to patient education that provides innovative, creative, and collaborative ways to disseminate the information.

Contact NxStage Medical UK

For further information about our products and services please contact:

NxStage Medical UK, Ltd.
St. Mary's Court, The Broadway
Amersham, Buckinghamshire, HP7 0UT
United Kingdom

Tel: 01494 590405

Customer Care and Technical Support

Tel: 0800 048 8352


NxStage Highlights

NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants

Dec 11, 2017 -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, celebrates the achievement of over five thousand patients having received a kidney transplantation after performing more frequent home hemodialysis with NxStage® System One.

Translations available: Spanish | French | German

NxStage Reports Second Quarter Financial Results

August 7, 2017 -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that its Board of Directors has unanimously approved a definitive agreement under which Fresenius Medical Care will acquire all of the outstanding shares of NxStage for $30.00 per share in a cash transaction valued at approximately $2 billion.

Translations available: Spanish | French | German

NxStage Medical Announces CE Mark for its NxGen Hemodialysis System

March 2, 2017 -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading medical technology company focused on advancing renal care, today announced that its next generation hemodialysis system has received CE Mark approval. This innovative system consists of new features and capabilities, including a new touchscreen user interface and integrated blood pressure monitor designed to enhance ease of use for patients performing home hemodialysis.

Translations available: Spanish | French | German

NxStage System One S launches in the US and UK

The NxStage System One S enables higher dialysate flow rates offering the potential to increase clearance.

24/7 Technical Support services now available

NxStage is now offering 24/7 Technical Support. Dialysis staff, patients, and care partners can call a single, dedicated free* phone number, regardless of day or time, to speak to a highly trained NxStage Technical Support specialist. Call 0800 048 8352 to receive immediate assistance for queries.   

*Charges may apply when calling from a mobile. As of 1 July 2015, as part of the UK Calling changes, all numbers starting with 0800 or 0808 will become free for consumers to call from mobile phones.

Dosing Calculator helps assist doctor prescribing

NxStage has launched the Dosing Calculator online tool that helps doctors and healthcare providers develop prescriptions tailored to patients' clinical and lifestyle objectives. The web-based tool is designed to provide prescription options with the NxStage System One*

*Specific dosing will vary by patient and individual responses to therapy. It is always the treating doctor's responsibility to ensure the appropriate prescription, therapy, and care plan are created for each individual patient.


February 28, 2018 to March 2, 2018
Biennial Austrailian & New Zealand Home Dialysis Conference Auckland, New Zealand
October 31, 2017 to November 5, 2017
American Society of Nephrology New Orleans, LA, USA
September 6, 2017 to September 9, 2017
ESPN Glasgow, Scotland
September 4, 2017 to September 6, 2017
Australia and New Zealand Society of Nephrology Darwin Convention Centre, Northern Territory
September 1, 2017 Home Dialysis Conference Manchester, UK
June 19, 2017 to June 21, 2017
BRA - UK Kidney Week 17 Liverpool, England
June 19, 2017 to June 21, 2017
Renal Society of Australasia Sydney, Australia
June 3, 2017 to June 6, 2017
ERA-EDTA Madrid, Spain
April 26, 2017 to April 28, 2017
British Renal Society Nottingham University, UK
APM1597 Rev. C